Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model

SIMPLE SUMMARY: Treatment with chimeric antigen receptor (CAR)-T cells has improved the prognosis of patients with non-Hodgkin lymphoma (NHL) substantially. Yet, as up to 60% of patients eventually relapse, insights into factors determining treatment response are highly warranted. We used mathematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller-Schoell, Anna, Puebla-Osorio, Nahum, Michelet, Robin, Green, Michael R., Künkele, Annette, Huisinga, Wilhelm, Strati, Paolo, Chasen, Beth, Neelapu, Sattva S., Yee, Cassian, Kloft, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199881/
https://www.ncbi.nlm.nih.gov/pubmed/34205020
http://dx.doi.org/10.3390/cancers13112782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199881/
https://www.ncbi.nlm.nih.gov/pubmed/34205020
http://dx.doi.org/10.3390/cancers13112782

Ejemplares similares